DR. JOSHUA BENNETT RUBIN, MD
Medical Practice at Childrens Pl, Saint Louis, MO

License number
Missouri 2004002774
Category
Medical Practice
Type
Pediatric Hematology-Oncology
Address
Address
1 Childrens Pl, Saint Louis, MO 63110
Phone
(314) 454-6018
(314) 454-2780 (Fax)

Personal information

See more information about JOSHUA BENNETT RUBIN at radaris.com
Name
Address
Phone
Joshua Rubin
185 Saylesville Dr, Chesterfield, MO 63017

Professional information

Joshua Bennett Rubin Photo 1

Joshua Bennett Rubin, Saint Louis MO

Specialties:
Pediatrics, Pediatric Hematology-Oncology, Hematology, Medical Oncology
Work:
Washington University at St. Louis
660 S Euclid Ave, Saint Louis, MO 63110
Education:
Yeshiva University (1994)


Joshua B Rubin Photo 2

Dr. Joshua B Rubin, Saint Louis MO - MD (Doctor of Medicine)

Specialties:
Pediatric Hematology & Oncology
Address:
Washington Univ Peds Hem/Onc
1 Childrens Pl SUITE 9S, Saint Louis 63110
(314) 454-6018 (Phone)
Certifications:
Pediatric Oncology & Pediatric Hematology, 2008, Pediatrics, 1997
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Washington Univ Peds Hem/Onc
1 Childrens Pl SUITE 9S, Saint Louis 63110
Barnes Jewish Hospital
1 Barnes Jewish Hospital Plz, Saint Louis 63110
Missouri Baptist Medical Center
3015 North Ballas Rd, Saint Louis 63131
Education:
Medical School
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1991
Chldns Hosp Boston
Dana Farber Cancer Inst


Joshua Rubin Photo 3

Phosphospecific Chemokine Receptor Antibodies

US Patent:
2009017, Jul 2, 2009
Filed:
Jun 30, 2006
Appl. No.:
11/994048
Inventors:
Joshua Rubin - Webster Groves MO, US
Andrew Kung - Walpole MA, US
Assignee:
National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Gov. - Bethesda MD
International Classification:
G01N 33/574, C07K 16/18, G01N 33/53, G01N 33/566
US Classification:
435 723, 5303879, 5303873, 5303877, 5303913, 435 721, 436501
Abstract:
The present invention provides chemokine receptor antibodies that selectively bind to an activated form of the receptor but not to a non activated form of the receptor. In particular, the current invention provides phospho specific chemokine receptor antibodies. The antibodies can be used in several diagnostic, screening and purification methods.